GSK Asks FDA To Mull Expansion Of NRT Indications
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Consumer Health division calls on FDA to consider expanding indications and use of over-the-counter nicotine replacement therapies to maximize the public health benefit